Ocadusertib - Eli Lilly and Company
Alternative Names: LY-3871801; R-552Latest Information Update: 28 Mar 2025
At a glance
- Originator Rigel Pharmaceuticals
- Developer Eli Lilly and Company; Rigel Pharmaceuticals
- Class Anti-inflammatories; Antirheumatics; Small molecules
- Mechanism of Action RIPK1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Rheumatoid arthritis
- No development reported Unspecified
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for phase-I development in Unspecified(In volunteers) in Singapore (PO, Suspension)
- 14 Nov 2024 Pharmacodynamics data from preclinical trials in Rheumatoid arthritis presented at the ACR Convergence 2024 (ACR-2024)
- 14 Nov 2024 Safety and pharmacokinetics data from a phase I trial in Rheumatoid arthritis presented at the ACR Convergence 2024 (ACR-2024)